We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma (PTCL), an aggressive blood cancer.
Central pathology review is a critical quality control measure for lymphoma diagnosis. Our central pathology review initiative is the first of its kind in PTCL research, enabling centralized diagnostic review across our global sites. This innovative approach ensures diagnostic accuracy and standardizes the classification of T-cell and natural killer (NK)-cell lymphomas, reducing diagnostic variability.
At PETAL, central pathology review involves our expert team of 20 blood cancer specialists who work together to better understand the different types of PTCLs. They compare their findings with previous diagnoses, use the latest classification systems, and create a standardized process to make sure patients around the world get an accurate and up-to-date diagnosis–including newly identified PTCL subtypes. Information gathered from this review will help investigators, pharmaceutical companies and regulatory agencies further differentiate PTCL subtypes.
Central pathology review will reduce misdiagnoses in our studies while capturing clinical data. Our concurrent genomic studies will advance the understanding of the molecular genetic features of PTCL subtypes, leading to the development of novel therapies.
This collaboration brings one of the most influential biotechnology leaders into PETAL’s growing network of partners committed to transforming outcomes in T-cell and NK-cell lymphomas. Regeneron’s support underscores the importance of PETAL’s innovative, cross-disciplinary approach to cancer research.
